ribosom
consist
two
ribonucleoprotein
subunit
act
cooper
mrna
translat
small
subunit
eukaryot
contain
mrnabind
site
path
along
mrna
progress
decod
centr
codon
read
trna
larg
subunit
eukaryot
site
peptid
bond
format
contain
polypeptid
exit
tunnel
trna
enter
ribosom
asit
move
psite
peptid
bond
format
deacetyl
trna
move
psite
esit
leav
ribosom
schme
ramakrishnan
standard
rule
decod
wellknown
ribosom
read
mrna
codon
codon
start
site
usual
aug
stop
signal
uaa
uag
uga
howev
genet
code
quit
univers
codon
differ
mean
certain
organel
small
number
organ
exampl
tryptophan
specifi
uga
human
mitochondria
barrel
reassign
affect
mrna
present
organel
organ
addit
altern
way
read
genet
code
describ
specif
mrna
extens
genet
code
name
recod
program
signal
present
specif
mrna
baranov
nami
translat
mrna
usual
accur
process
estim
frequenc
miscod
per
codon
saccharomyc
cerevisia
per
codon
escherichia
coli
kramer
farabaugh
fanminogu
bedwel
howev
wellknown
frequenc
unconvent
decod
recod
may
high
grentzmann
nami
pennel
recod
event
occur
competit
standard
decod
make
possibl
synthesi
two
polypeptid
precis
ratio
singl
mrna
recod
may
occur
translat
elong
frameshift
hop
stopgo
termin
stop
codon
readthrough
gesteland
atkin
nami
atkin
recod
may
extend
gene
express
repertoir
sever
way
may
lead
product
divers
set
protein
singl
mrna
blinkowa
walker
flower
mchenri
tsuchihashi
kornberg
morri
lundblad
typic
exampl
found
cerevisia
two
polypeptid
gener
mrna
correspond
gene
frameshift
event
morri
lundblad
asakura
similar
mechan
involv
express
asakura
recod
may
lead
incorpor
nonstandard
amino
acid
selenocystein
uga
codon
pyrrolysin
uag
codon
leinfeld
nami
allmang
krol
recod
event
mostli
occur
virus
mobil
element
play
essenti
role
life
cycl
regul
baranov
girnari
mazaur
chung
sever
virus
make
use
frameshift
produc
enzym
involv
replic
case
retrovirus
sever
eukaryot
positivestrand
rna
virus
doublestrand
rna
virus
yeast
plant
rna
virus
bacteriophag
review
see
brierley
do
ramo
ribosom
frameshift
frequent
use
product
replicas
involv
synthesi
gagpol
gagpropol
polyprotein
retrovirus
essenti
product
rnadepend
rna
polymeras
number
virus
final
recod
regul
gene
express
autoregulatori
loop
mediat
rapid
regul
fluctuat
environ
wellillustr
frameshift
found
bacteri
prfb
eukaryot
antizym
gene
craigen
caskey
matsufuji
stimulatori
element
frameshift
site
uga
stop
codon
recogn
high
level
competit
termin
frameshift
shift
favour
termin
lead
decreas
concentr
decreas
level
lead
decreas
translat
termin
uga
codon
therebi
increas
frameshift
effici
antizym
mrna
high
polyamin
level
stimul
frameshift
requir
synthesi
function
antizym
product
larger
amount
antizym
lead
inhibit
first
step
polyamin
biosynthesi
pathway
result
gener
decreas
polyamin
concentr
turn
decreas
frameshift
effici
altern
recod
may
also
regul
gene
express
mrna
level
prevent
stimul
mrna
degrad
nonsensemedi
mrna
decay
nmd
pathway
plant
seem
like
recod
event
larg
underidentifi
misannot
genom
clearli
present
life
form
significantli
increas
divers
polypeptid
produc
cell
focu
two
type
recod
event
frameshift
found
two
virus
major
public
health
concern
hiv
sarscov
stop
codon
readthrough
major
medic
implic
review
aim
highlight
essenti
contribut
fundament
research
yeast
cerevisia
improv
understand
complex
event
possibl
develop
novel
treatment
futur
program
frameshift
signal
prf
among
frequent
identifi
recod
site
minim
prf
consist
slipperi
sequenc
one
two
trna
shift
read
frame
stimulatori
element
secondari
structur
brierley
frameshift
site
may
consist
heptamer
slipperi
sequenc
gener
structur
x
xxi
yyz
tetramer
sequenc
yyz
initi
read
frame
indic
separ
secondari
structur
spacer
region
precis
length
composit
region
play
import
role
correct
present
stimulatori
element
ribosom
maxim
frameshift
effici
kollmu
konto
bertrand
variou
secondari
structur
found
increas
effici
stem
loop
kiss
loop
pseudoknot
etc
fig
secondari
structur
induc
strong
paus
ribosom
elong
somogyi
lopinski
konto
paus
suffici
induc
frameshift
mechan
structur
stimul
long
matter
debat
napthin
giedroc
plant
plant
dinman
nami
recent
provid
partial
solut
enigma
use
cryoem
approach
studi
paus
ribosom
frameshift
pseudoknot
nami
observ
direct
interact
pseudoknot
ribosom
propos
new
model
stimul
secondari
structur
result
confirm
group
provid
addit
support
origin
model
ortiz
leger
pseudoknot
prevent
complet
full
cycl
transloc
trap
efg
prokaryot
within
ribosom
distort
trna
intermedi
state
transloc
moran
flanagan
thu
frameshift
power
tool
studi
mechan
read
frame
mainten
translat
elong
frameshift
site
frequent
found
virus
includ
sarscov
slipperi
sequenc
follow
either
pseudoknot
found
gag
pol
gene
orf
review
see
brierley
do
ramo
frameshift
first
identifi
vitro
translat
assay
jack
consist
slipperi
sequenc
u
uuu
uua
follow
stimulatori
element
howev
recent
studi
focus
architectur
secondari
structur
entir
rna
genom
indic
frameshift
site
part
larger
threehelix
structur
stimulatori
element
call
slipperi
sequenc
pair
upstream
region
form
second
helix
two
helic
stabil
anchor
helix
creat
larger
structur
watt
fig
frameshift
effici
never
test
broad
context
rna
motif
may
involv
regul
presenc
ribosom
may
induc
structur
rearrang
inde
ribosom
probabl
first
melt
upper
stem
becom
avail
basepair
free
nucleotid
locat
slipperi
sequenc
stem
loop
blue
fig
wilson
first
provid
vivo
demonstr
frameshift
event
cerevisia
insert
gagpol
fragment
contain
potenti
frameshift
site
without
stimulatori
element
yeast
express
plasmid
upstream
ifn
cdna
monitor
product
frameshift
protein
western
blot
work
suffer
absenc
stimulatori
element
yet
identifi
lack
identif
stimulatori
element
initi
work
long
led
research
hypothes
secondari
structur
present
hiv
slipperi
site
jack
wilson
clear
stimulatori
secondari
structur
requir
maxim
frameshift
effici
although
precis
natur
structur
remain
unclear
long
time
nmr
studi
shown
stimulatori
element
consist
highli
stabl
apic
stem
form
continu
helix
cap
noncanon
basepair
acaa
tetraloop
stapl
butcher
less
stabl
lower
stem
also
present
separ
upper
stem
threepurin
bulg
introduc
bend
two
stem
stapl
butcher
fig
bidou
show
dual
report
system
yeast
direct
correl
hiv
frameshift
effici
stabil
stem
loop
analys
studi
upper
part
complet
stimulatori
element
observ
nmr
condit
stabil
structur
clearli
link
frameshift
effici
structur
recent
identifi
basi
complet
genom
sequenc
would
interest
assess
frameshift
effici
complet
sequenc
structur
tetraloop
reminisc
tetraloop
motif
found
rnaseiii
recognit
site
cerevisia
stapl
butcher
acaa
motif
poorli
recogn
rnaseiii
might
possibl
engin
cerevisia
rnaseiii
select
target
tetraloop
would
necessari
produc
protein
cell
therapeut
approach
yet
develop
would
provid
interest
approach
limit
prolifer
similar
slippag
effici
hiv
frameshift
site
vivo
yeast
vitro
mammalian
system
demonstr
high
level
conserv
frameshift
mechan
moreov
lack
stimul
frameshift
virusinfect
cell
demonstr
absenc
specif
autoregulatori
control
involv
host
hivencod
factor
hiv
frameshift
cassan
demonstr
frameshift
conserv
yeast
human
pave
way
use
yeast
mutant
analys
retrovir
frameshift
alreadi
report
sever
group
sarscov
novel
coronaviru
carri
frameshift
signal
plant
dinman
minim
frameshift
signal
viru
u
uua
aac
slipperi
sequenc
stimulatori
structur
fold
pseudoknot
do
ramo
fig
pseudoknot
sever
unusu
featur
includ
third
stem
loop
presenc
two
unpair
adenosin
residu
within
structur
baranov
plant
dinman
brierley
do
ramo
plant
dinman
demonstr
abil
new
site
frameshift
cerevisia
frequenc
frameshift
yeast
much
lower
coronaviru
site
test
yeast
infecti
bronchiti
viru
ibv
may
indic
exist
subtl
differ
term
frameshift
mechan
inde
import
unpair
adenosin
residu
remain
unclear
part
pseudoknot
thought
lie
outsid
ribosom
would
interest
investig
possibl
bind
transact
factor
although
bind
factor
never
detect
wellstudi
ibv
coronaviru
pseudoknot
yeast
mutant
known
specif
defect
frameshift
peltz
mutant
carri
alter
form
ribosom
protein
ribosom
peptidyltransf
centr
strain
report
slightli
higher
sarscov
frameshift
effici
wildtyp
strain
plant
dinman
first
demonstr
newli
discov
frameshift
site
use
mechan
analys
previous
sarscov
pose
major
public
health
issu
elucid
mechan
viral
frameshift
therefor
key
first
step
toward
develop
new
antivir
strategi
shown
sever
retrovirus
includ
hiv
modul
frameshift
effici
significantli
reduc
viral
infect
cultur
cell
hung
inde
viral
rna
dimer
export
strongli
affect
chang
gaggagpol
protein
ratio
kay
lever
shehuxhilaga
variou
compound
includ
antibiot
modifi
oligoribonucleotid
shown
affect
frameshift
vitro
ex
vivo
vicker
ecker
aupeixscheidl
toulm
howev
extent
compound
abl
block
viral
propag
vivo
remain
matter
debat
nevertheless
frameshift
constitut
potenti
target
treatment
aim
interfer
viral
multipl
inde
despit
high
level
variabl
hiv
genom
sequenc
frameshift
site
strongli
conserv
among
subtyp
hiv
group
moreov
frameshift
effici
lie
within
narrow
rang
subtyp
group
suggest
modif
toler
step
viru
cycl
baril
mani
stage
hiv
replic
cycl
target
drug
block
viral
replic
howev
past
clinic
experi
indic
resist
variant
like
emerg
make
necessari
identifi
addit
target
treatment
futur
target
new
drug
identifi
translat
step
viral
cycl
fig
larg
translat
machineri
cell
use
translat
viral
protein
drug
prevent
translat
viral
protein
would
therefor
also
affect
cellular
protein
product
target
frameshift
step
may
make
possibl
circumv
problem
hung
potenti
allow
develop
new
treatment
specif
target
synthesi
viral
protein
one
potenti
issu
develop
approach
concern
possibl
cellular
gene
may
use
frameshift
normal
express
date
one
mammalian
gene
shown
use
frameshift
shigemoto
manktelow
clark
gene
express
exclus
embryogenesi
yet
exclud
possibl
yet
unidentifi
gene
make
use
recod
event
express
care
evalu
riskbenefit
ratio
therefor
requir
thu
prime
import
design
effici
tool
identifi
recod
site
genom
last
decad
sever
bioinformat
approach
develop
purpos
see
refer
nami
studi
date
focus
cerevisia
genom
yeast
high
qualiti
low
frequenc
sequenc
error
wellidentifi
intron
cluster
small
number
gene
extens
approach
complex
genom
requir
current
limit
difficulti
intron
identif
complex
mrna
popul
gener
altern
splice
hope
develop
deep
sequenc
approach
partial
resolv
problem
make
possibl
develop
accur
mrna
databas
conserv
frameshift
mechan
cerevisia
mammal
make
possibl
screen
activ
molecul
target
step
yeast
model
occupi
key
role
search
new
activ
drug
frameshift
sarscov
inde
two
group
alreadi
carri
genet
screen
cerevisia
view
isol
mutat
affect
frameshift
effici
identifi
chromosom
mutat
call
mof
mainten
frame
dinman
wickner
if
increas
frameshift
lee
howev
mutat
subsequ
found
inactiv
protein
respect
two
protein
involv
degrad
mrna
contain
prematur
termin
codon
ptc
nmd
pathway
cui
effect
frameshift
effici
per
se
bidou
harger
dinman
ribosom
protein
translat
factor
may
also
affect
frameshift
potenti
protein
use
treatment
remain
unclear
essenti
character
role
protein
frameshift
mechan
identif
new
target
treatment
organ
use
standard
genet
code
translat
termin
one
three
stop
codon
uaa
uga
uag
enter
ribosom
asit
fig
unlik
sens
codon
recogn
trna
stop
codon
recogn
group
protein
call
class
releas
factor
frolova
translat
termin
effici
depend
competit
stop
codon
recognit
releas
factor
decod
nearcogn
trna
pair
two
three
base
stop
codon
eukaryot
two
eukaryot
releas
factor
mediat
translat
termin
stansfield
saccharomyc
cerevisia
prove
power
tool
identif
character
eukaryot
releas
factor
frolova
full
partial
xray
structur
determin
protein
provid
insight
function
song
cheng
protein
recogn
stop
codon
ntermin
domain
trigger
peptidyltrna
hydrolysi
activ
peptidyl
transferas
centr
ribosom
highli
conserv
nik
ggq
motif
domain
respect
frolova
ctermin
domain
involv
bind
eurwilaichitr
overal
shape
human
mimic
trna
posit
function
motif
ggq
nik
peptidyl
centr
decod
site
ribosom
respect
molecular
mechan
underli
process
remain
unclear
eukaryot
presenc
stop
codon
ribosom
asit
necessit
conform
rearrang
activ
gtpase
activ
gtp
hydrolysi
facilit
correct
posit
ggq
motif
peptidyl
transferas
centr
catalysi
peptidyltrna
cleavag
act
proofread
factor
termin
salasmarco
bedwel
despit
competit
nearcogn
trna
releas
factor
fig
littl
incorpor
trna
observ
normal
condit
error
rate
standard
yeast
strain
nami
nucleotid
around
stop
codon
stop
codon
context
key
determin
termin
effici
reprogramm
stop
codon
increas
readthrough
effici
level
high
develop
power
report
system
cerevisia
base
insert
stop
codon
gene
combinatori
analysi
stop
codon
context
nami
encod
pribosylaminoimidazol
carboxylas
ec
respons
degrad
red
pigment
aminoimidazol
ribotid
shown
yeast
coloni
chang
colour
red
white
readthrough
level
gene
exceed
nami
studi
demonstr
cerevisia
six
downstream
nucleotid
play
crucial
role
stop
codon
suppress
effici
bonetti
nami
similar
find
report
plant
skuzeski
mous
cell
cassan
rousset
stop
codon
readthrough
first
recogn
mechan
virus
regul
ratio
two
protein
gener
translat
mrna
gesteland
atkin
also
describ
organ
nami
factor
govern
select
nearcogn
trna
remain
unknown
nonetheless
conserv
stop
codon
readthrough
yeast
mammal
stahl
made
possibl
use
cerevisia
character
mechan
detail
includ
particular
role
nucleotid
surround
stop
codon
mani
genet
disord
cancer
involv
ptc
use
drug
induc
ptc
readthrough
would
pave
way
develop
mani
novel
treatment
protocol
promis
approach
could
least
theoret
appli
stop
codon
diseas
inde
ptc
account
inherit
diseas
includ
cystic
fibrosi
cf
haemophilia
retin
pigmentosa
duchenn
muscular
dystrophi
dmd
zingman
mutat
give
rise
ptc
lead
complet
loss
protein
function
decreas
mrna
level
nmd
first
attempt
suppress
ptc
eukaryot
cell
involv
use
aminoglycosid
larg
famili
structur
relat
antibiot
prokaryot
eukaryot
aminoglycosid
induc
miscod
mimick
chang
conform
rrna
gene
would
induc
correct
pair
therebi
compromis
integr
proofread
translat
burk
mogg
carter
pape
palmer
first
demonstr
paromomycin
could
abolish
nonsens
mutat
cerevisia
year
later
burk
mogg
show
paromomycin
partial
restor
synthesi
function
protein
mutant
gene
uag
nonsens
mutat
cultur
mammalian
cell
feasibl
extend
approach
therapeut
strategi
human
diseas
first
demonstr
work
sweeney
group
demonstr
gentamicin
partli
restor
product
fulllength
dystrophin
mdx
mice
carri
xlink
muscular
dystrophi
mutat
mdx
bartondavi
semin
work
incit
consider
interest
translat
termin
target
treatment
mani
subsequ
studi
valid
approach
sever
genet
diseas
model
row
clanci
strategi
base
stimul
ptc
readthrough
variou
molecul
includ
gentamicin
negamycin
recent
character
tylosin
member
macrolid
famili
welch
rosinarbesfeld
induc
error
termin
process
hainrichson
bedwel
also
shown
gentamicin
restor
product
cystic
fibrosi
transmembran
conduct
regul
cftr
bronchial
cell
line
carri
nonsens
mutat
cftr
gene
similarli
hurler
syndrom
fibroblast
cell
line
heterozyg
stop
mutat
display
signific
increas
level
cultur
presenc
gentamicin
keel
bedwel
sever
clinic
trial
also
provid
preliminari
evid
gentamicin
abolish
stop
mutat
dmd
cf
patient
remain
determin
whether
result
protein
level
suffici
high
therapeut
benefit
wilschanski
wagner
politano
recent
collabor
clinic
trial
cf
patient
variou
nonsens
mutat
patient
treat
intraven
gentamicin
everi
day
day
clinic
benefit
observ
subset
patient
signific
alter
cftrmediat
chlorid
transport
nasal
sweat
gland
epithelia
correl
level
readthrough
obtain
improv
clinic
statu
observ
clinic
trial
first
show
parenter
administr
gentamicin
dose
previous
demonstr
safe
could
benefici
clinic
effect
sermetgaudelu
new
molecul
ataluren
discov
ptc
therapeut
biotech
compani
current
undergo
evalu
use
dmd
cf
clinic
trial
howev
effect
readthrough
effici
remain
matter
debat
follow
public
studi
demonstr
potent
competit
inhibitor
firefli
luciferas
report
commonli
use
quantifi
ptc
readthrough
level
auld
peltz
bias
probabl
occur
frequent
highlight
import
use
differ
report
system
process
drug
screen
prevent
isol
compound
act
specif
report
system
anoth
major
issu
identifi
mani
studi
concern
differ
sensit
nonsens
mutat
readthroughpromot
drug
result
subset
ptccarri
patient
would
benefit
pharmacolog
treatment
type
bidou
interestingli
analys
reveal
mdx
mutat
direct
low
level
readthrough
despit
strong
stimul
dystrophin
accumul
observ
initi
studi
bartondavi
colleagu
may
reflect
inhibit
nmd
pathway
antibiot
stabil
mrna
molecul
read
ribosom
allamand
abil
drug
suppress
ptc
depend
sever
factor
includ
ident
stop
codon
context
surround
first
nucleotid
stop
codon
report
associ
high
level
readthrough
presenc
absenc
aminoglycosid
manuvakhova
moreov
shown
cultur
mammalian
cell
c
posit
could
also
associ
moder
readthrough
level
bidou
impact
nucleotid
larg
depend
surround
nucleotid
unfortun
factor
determin
readthrough
effici
remain
unknown
make
imposs
predict
effici
drug
promot
readthrough
given
mutat
bedwel
laboratori
among
first
analys
ptc
suppress
natur
gene
context
examin
suppress
ptc
mutat
yeast
gene
encod
protein
highli
conserv
among
member
atpbind
cassett
transport
famili
fearon
human
cftr
defect
individu
cf
also
belong
protein
famili
mutat
examin
chosen
ptc
correspond
residu
cftr
gene
report
caus
less
sever
pulmonari
involv
missens
mutat
suggest
lowlevel
suppress
stop
codon
may
occur
inde
result
indic
ptc
could
suppress
frequenc
high
yeast
author
show
limit
sequenc
context
surround
site
contain
suffici
inform
abolish
translat
termin
fearon
also
highlight
hierarchi
three
stop
codon
cerevisia
show
amber
uag
codon
suppress
effici
opal
uga
ochr
uaa
codon
similar
hierarchi
gener
found
mammalian
cell
cultur
experi
bedwel
group
also
demonstr
mechan
respons
suppress
trna
mispair
rather
ribosom
hop
previous
shown
occur
case
e
coli
weiss
group
also
analys
aminoacid
sequenc
readthrough
protein
demonstr
readthrough
uag
codon
mediat
incorpor
least
three
nearcogn
trna
tyrosin
lysin
tryptophan
unfortun
incorpor
amino
acid
place
ptc
demonstr
studi
consequ
potenti
effect
readthrough
drug
stop
codon
context
incorpor
nearcogn
trna
unknown
character
requir
stabil
andor
activ
result
fulllength
protein
may
critic
depend
amino
acid
incorpor
allamand
studi
could
carri
cerevisia
conveni
report
system
alreadi
exist
mammalian
cell
dedic
report
system
yet
construct
key
issu
analys
low
level
stop
codon
readthrough
presenc
psi
prion
yeast
may
make
possibl
overcom
problem
extent
psi
prion
form
encod
gene
cerevisia
teravanesyan
wickner
chang
conform
gener
prionaggreg
form
result
impair
termin
activ
higher
level
stop
codon
readthrough
facilit
analysi
consider
moreov
mani
mutant
strain
yeast
one
releas
factor
affect
avail
could
prove
use
studi
stop
codon
readthrough
genet
context
weak
termin
aminoglycosid
toxic
renal
cochlear
vestibular
side
effect
major
concern
clinic
use
kahlmet
dahlag
howev
side
effect
directli
associ
abil
aminoglycosid
suppress
ptc
therefor
possibl
identifi
compound
induc
highli
effici
codon
readthrough
lower
level
toxic
compound
aminoglycosid
shown
increas
readthrough
compound
includ
negamycin
arakawa
welch
two
molecul
report
fewer
side
effect
remain
unclear
whether
induc
readthrough
significantli
effici
gentamicin
tylosin
also
shown
induc
stop
codon
readthrough
effici
ptc
apc
gene
rosinarbesfeld
drug
potenti
interest
stimul
readthrough
strongli
limit
toxic
anim
belong
macrolid
famili
member
bind
polypeptid
exit
channel
larg
subunit
ribosom
hansen
disaccharid
moieti
molecul
extend
toward
catalyt
centr
ribosom
macrolid
bind
induc
rearrang
base
e
coli
number
gener
extend
conform
allow
format
coval
bond
macrolid
rearrang
differ
induc
aminoglycosid
two
class
drug
could
therefor
potenti
use
togeth
gener
high
level
readthrough
give
benefici
therapeut
effect
make
possibl
use
compound
lower
less
toxic
concentr
consider
effort
current
made
develop
new
readthroughinduc
molecul
specif
termin
reaction
less
toxic
kaufman
approach
would
benefit
consider
develop
new
screen
procedur
saccharomyc
cerevisia
host
choic
screen
system
use
screen
chemic
librari
basal
readthrough
condit
protein
produc
small
amount
coloni
red
pilot
experi
shown
treatment
aminoglycosid
result
white
coloni
system
use
highthroughput
screen
compound
test
chemic
modifi
drug
aminoglycosid
deriv
inde
improv
understand
bind
aminoglycosid
eukaryot
rna
would
make
possibl
design
specif
compound
addit
cerevisia
also
ideal
model
organ
power
genet
screen
make
possibl
identifi
biolog
entiti
target
isol
compound
revers
screen
assay
bach
tribouillard
conserv
translat
fidel
mechan
yeast
cerevisia
mammal
made
possibl
develop
use
yeast
model
organ
mani
studi
made
use
model
deciph
role
variou
compon
translat
apparatu
determin
effect
drug
modifi
translat
accuraci
saccharomyc
cerevisia
instrument
identif
character
eukaryot
releas
factor
also
use
select
character
larg
number
mutat
affect
translat
fidel
variou
stage
includ
read
frame
mainten
termin
accuraci
mutant
current
use
studi
mechan
translat
fidel
one
current
challeng
field
elucid
mechan
underli
contribut
nucleotid
surround
termin
codon
readthrough
effici
socal
context
effect
readthrough
level
may
differ
factor
nonsens
mutat
molecular
mechan
mediat
effect
stop
codon
context
remain
unknown
similarli
know
noth
signal
involv
differ
respons
aminoglycosid
treatment
believ
case
yeast
cerevisia
prove
potent
tool
deciph
basi
actor
interact
mechan
work
develop
procedur
screen
chemic
librari
cerevisia
identifi
drug
act
differ
stage
gene
express
promis
far
frameshift
concern
approach
may
open
new
possibl
develop
innov
treatment
protocol
combat
retrovirus
ration
drug
design
would
also
interest
altern
would
requir
accur
knowledg
structur
factor
involv
frameshift
ribosom
protein
target
choic
modul
frameshift
effici
littl
known
precis
role
frame
mainten
also
seem
like
sever
protein
may
involv
associ
ribosom
subunit
limit
use
drug
target
protein
termin
step
biochem
wellcharacter
eukaryot
littl
known
structur
termin
complex
within
ribosom
ration
design
molecul
interf
step
saccharomyc
cerevisia
undoubtedli
continu
use
power
model
deciph
complex
structur
function
interact
differ
player
rrna
protein
trna
releas
factor
etc
dictat
readthrough
effici
may
also
contribut
identif
new
molecul
interf
either
frame
mainten
termin
effici
